Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13675825 | 1.00 | SIGMAR1 (0.70) | SIGMAR1POLBLTA4HBCHELMNA | |
| SCHEMBL172363 | 1.00 | SIGMAR1 (0.70) | SIGMAR1POLBLTA4HBCHELMNA | |
| SCHEMBL10943350 | 0.89 | SIGMAR1 (0.54) | SIGMAR1LTA4HBCHECYP3A4SMN1; SMN2 | |
| SCHEMBL13200644 | 0.85 | SIGMAR1 (0.52) | SIGMAR1LTA4HCYP3A4SMN1; SMN2 | |
| SCHEMBL8826024 | 0.84 | SIGMAR1 (0.51) | SIGMAR1LTA4HBCHEKDM4ESMN1; SMN2 | |
| SCHEMBL8691568 | 0.84 | SIGMAR1 (0.51) | SIGMAR1LTA4HBCHEKDM4ESMN1; SMN2 | |
| SCHEMBL8692762 | 0.84 | SIGMAR1 (0.51) | SIGMAR1LTA4HBCHEKDM4ESMN1; SMN2 | |
| SCHEMBL172531 | 0.83 | SIGMAR1 (0.66) | SIGMAR1POLBBCHELMNATAAR1 | |
| N-Benzylamphetamine SCHEMBL2451256 | 0.83 | SIGMAR1 (1.00) | SIGMAR1POLBLMNATAAR1SLC18A2 | |
| N-Benzylamphetamine SCHEMBL2795222 | 0.83 | SIGMAR1 (1.00) | SIGMAR1POLBLMNATAAR1SLC18A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4954499-A | Pyridazinone derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1990-09-04 | — | — | US | claimed |
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4469438-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-11753418-B2 | Compounds for the modulation of Myc activity | SYROS PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-3492104-B1 | USE OF 10H-BENZO [G] PTERIDIN-2,4-DION DERIVATIVES | TRIOPTOTEC GMBH (DE) | 2023-02-15 | — | — | EP | disclosed |
| EP-3586632-B1 | 10H-BENZO[G]PTERIDINE-2,4-DIONE DERIVATIVES, METHOD FOR PRODUCING SAME AND USE OF SAME | TRIOPTOTEC GMBH (DE) | 2022-09-28 | — | — | EP | disclosed |
| US-20220048927-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2022-02-17 | — | — | US | disclosed |
| US-11124527-B2 | Compounds for the modulation of Myc activity | SYROS PHARMACEUTICALS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| EP-1597292-A2 | PROCESS FOR HOMO- OR COPOLYMERIZATION OF CONJUGATED OLEFINES | DOW GLOBAL TECHNOLOGIES INC. (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004076504-A2 | PROCESS FOR HOMO- OR COPOLYMERIZATION OF CONJUGATED OLEFINES | DOW GLOBAL TECHNOLOGIES, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
| US-4853386-A | INHIBITORS OF SRS-A(SLOW REACTING SUBSTANCE OF ANAPHYLAXIS) FROM LUNG TISSUES | BOEHRINGER MANNHEIM GMBH (DE) | 1989-08-01 | — | — | US | disclosed |
| EP-0252504-A1 | Diphosphonic-acid derivatives, process for their preparation and medicines containing these compounds | Roche Diagnostics GmbH (DE) | 1988-01-13 | — | — | EP | disclosed |
| US-4688059-A | 3-ARYL(OR HETEROARYL)-3-(OXY OR THIO)PHTHALIDE AS REAGENT IN CARBONLESS DUPLICATING SYSTEM | THE HILTON-DAVIS CHEMICAL CO. (US) | 1987-08-18 | — | — | US | disclosed |
| US-4661605-A | CARBONLESS CUPLICATION AND THERMAL MARKING SYSTEMS | THE HILTON-DAVIS CHEMICAL CO. (US) | 1987-04-28 | — | — | US | disclosed |
| US-4535172-A | FOR CARBONLESS DUPLICATING AND THERMAL MARKING SYSTEMS | THE HILTON-DAVIS CHEMICAL CO. (US) | 1985-08-13 | — | — | US | disclosed |
| US-4528136-A | Process for preparing 2-[bis(aryl)methyl]benzoic acids | THE HILTON-DAVIS CHEMICAL CO. (US) | 1985-07-09 | — | — | US | disclosed |
| US-4399291-A | CONDENSATION OF A BENZALDEHYDE, AN ANILINE, AN AMINOBENZOIC ACID; OXIDATION | STERLING DRUG INC. (US) | 1983-08-16 | — | — | US | disclosed |
| EP-0082394-A2 | A process for the production of aminophthalides and amino benzoic acids | STERLING DRUG INC. (US) | 1983-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | CNKSR1, UGT1A1, REV1 | SIGMAR1 1744/4885POLB 2100/4885LTA4H 1216/4885 |
| US-11753418-B2 | Compounds for the modulation of Myc activity | MYC, MYCBP, MYCBP2 | SIGMAR1 4177/4885POLB 1570/4885LTA4H 2595/4885 |
| US-20220048927-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | MYC, MYCBP, MYCBP2 | SIGMAR1 4177/4885POLB 1570/4885LTA4H 2595/4885 |
| US-11124527-B2 | Compounds for the modulation of Myc activity | MYC, MYCBP, MYCBP2 | SIGMAR1 4177/4885POLB 1570/4885LTA4H 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.